Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityOther Non-Current LiabilitiesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Cash & Current Investments (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Cash & Current Investments readings, the most recent being $45622.0 for Q3 2025.

  • On a quarterly basis, Cash & Current Investments rose 859.45% to $45622.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $45622.0, a 859.45% increase, with the full-year FY2024 number at $49404.0, down 7.19% from a year prior.
  • Cash & Current Investments hit $45622.0 in Q3 2025 for Goldenwell Biotech, down from $76507.0 in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $248569.0 in Q1 2021 to a low of $4755.0 in Q3 2024.
  • Median Cash & Current Investments over the past 5 years was $45996.0 (2022), compared with a mean of $87931.7.
  • Biggest five-year swings in Cash & Current Investments: crashed 82.54% in 2022 and later soared 859.45% in 2025.
  • Goldenwell Biotech's Cash & Current Investments stood at $213556.0 in 2021, then plummeted by 78.46% to $45996.0 in 2022, then rose by 15.73% to $53231.0 in 2023, then dropped by 7.19% to $49404.0 in 2024, then fell by 7.66% to $45622.0 in 2025.
  • The last three reported values for Cash & Current Investments were $45622.0 (Q3 2025), $76507.0 (Q2 2025), and $17127.0 (Q1 2025) per Business Quant data.